Payment overview · 2025
General Payments
$2,522.23
113 reported records · 18 companies
Healthcare provider profile · identity verified
Babu Shiva Kumar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAMDEN, CT · NPI 1295721942
Verified facts
What the public records show
CMS Open Payments records show Babu Shiva Kumar, MD received $2,522.23 in general payments during 2025 across 113 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $754.97 | 29.9% | 27 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $286.42 | 11.4% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $259.62 | 10.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $245.22 | 9.7% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $189.86 | 7.5% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.12 | 5.0% | 7 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $113.57 | 4.5% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $112.39 | 4.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.29 | 3.3% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $74.99 | 3.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.36 | 2.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $55.07 | 2.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.25 | 2.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.27 | 1.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.55 | 0.9% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $20.56 | 0.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.92 | 0.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.80 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,522.23 | 113 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $533.14 | 16 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $319.52 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $286.42 | 15 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $224.75 | 13 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $189.86 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $125.12 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $125.12 | 7 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $113.57 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $112.39 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $74.99 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $69.05 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $59.36 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $56.30 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $53.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.89 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.27 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.68 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 203 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
203 | 62 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
192 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1011 | 334 |
| Amlodipine Besylate | Amlodipine Besylate | 953 | 280 |
| Atorvastatin Calcium | Atorvastatin Calcium | 902 | 239 |
| Levothyroxine Sodium | Levothyroxine Sodium | 746 | 190 |
| Metformin Hcl | Metformin Hcl | 583 | 156 |
| Losartan Potassium | Losartan Potassium | 488 | 135 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 422 | 150 |
| Lisinopril | Lisinopril | 392 | 100 |
| Doxycycline Hyclate | Doxycycline Hyclate | 385 | 282 |
| Pravastatin Sodium | Pravastatin Sodium | 374 | 100 |
| Omeprazole | Omeprazole | 367 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 296 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 282 | 81 |
| Gabapentin | Gabapentin | 241 | 69 |
| Montelukast Sodium | Montelukast Sodium | 237 | 67 |
| Metformin Hcl Er | Metformin Hcl | 233 | 66 |
| Farxiga | Dapagliflozin Propanediol | 203 | 62 |
| Ozempic | Semaglutide | 192 | 42 |
| Simvastatin | Simvastatin | 188 | 42 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 179 | 140 |
| Januvia | Sitagliptin Phosphate | 169 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 41 |
| Furosemide | Furosemide | 156 | 50 |
| Carvedilol | Carvedilol | 143 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 46 |
| Eliquis | Apixaban | 134 | 37 |
| Ezetimibe | Ezetimibe | 134 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 57 |
| Jardiance | Empagliflozin | 124 | 38 |
| Potassium Chloride | Potassium Chloride | 123 | 42 |
| Glimepiride | Glimepiride | 121 | 46 |
| Allopurinol | Allopurinol | 108 | 35 |
| Trazodone Hcl | Trazodone Hcl | 107 | 25 |
| Atenolol | Atenolol | 91 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 23 |
| Tradjenta | Linagliptin | 90 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 41 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 88 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 21 |
| Glipizide | Glipizide | 85 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 62 |
| Nystatin | Nystatin | 78 | 37 |
| Sertraline Hcl | Sertraline Hcl | 78 | 26 |
| Buspirone Hcl | Buspirone Hcl | 76 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 23 |
| Meclizine Hcl | Meclizine Hcl | 73 | 33 |
| Famotidine | Famotidine | 72 | 24 |
| Alprazolam | Alprazolam | 70 | 13 |
| Prednisone | Prednisone | 69 | 34 |
| Alendronate Sodium | Alendronate Sodium | 66 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 66 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 65 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | suppressed |
| Methylprednisolone | Methylprednisolone | 61 | 48 |
| Azithromycin | Azithromycin | 58 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 14 |
| Valsartan | Valsartan | 55 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 54 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 12 |
| Glipizide Er | Glipizide | 54 | 12 |
| Spironolactone | Spironolactone | 54 | 16 |
| Cefdinir | Cefdinir | 52 | 47 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 13 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 49 | 15 |
| Linzess | Linaclotide | 49 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 48 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Lidocaine | Lidocaine | 47 | suppressed |
| Lorazepam | Lorazepam | 47 | suppressed |
| Cephalexin | Cephalexin | 46 | 40 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 11 |
| Methocarbamol | Methocarbamol | 44 | 23 |
| Vascepa | Icosapent Ethyl | 44 | 11 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Repatha Sureclick | Evolocumab | 43 | 17 |
| Ketoconazole | Ketoconazole | 42 | 18 |
| Baclofen | Baclofen | 41 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Valacyclovir | Valacyclovir Hcl | 40 | 25 |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 36 |
| Tramadol Hcl | Tramadol Hcl | 37 | 14 |
| Colchicine | Colchicine | 36 | 16 |
| Mirtazapine | Mirtazapine | 36 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 31 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Levemir Flexpen | Insulin Detemir | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Fluconazole | Fluconazole | 28 | 15 |
| Meloxicam | Meloxicam | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 21 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Tobramycin | Tobramycin | 20 | 18 |
| Topiramate | Topiramate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | 13 |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Epinephrine | Epinephrine | 13 | 11 |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dentagel | Fluoride (Sodium) | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levocarnitine | Levocarnitine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Thiothixene | Thiothixene | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,522.23 · 113 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, FARXIGA, FASENRA, FREESTYLE LIBRE 3, GLYCATE, ID NOW INSTRUMENT, JARDIANCE, LEQVIO, MOUNJARO, NEXLETOL, NUZYRA, OFEV, OTEZLA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XHANCE, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error